The contribution of HGAL/GCET2 in immunohistological algorithms: a comparative study in 424 cases of nodal diffuse large B-cell lymphoma

Gualco, Gabrıela; Bacchi, Lívia Moscardi; Domeny-Duarte, Pollyanna; Natkunam, Yasodha; Bacchi, Carlos E.

doi:10.1038/modpathol.2012.119

Cited by 8 publications

(9 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Human germinal center‐associated lymphoma (HGAL) is a B‐cell specific marker the expression of which is observed in the cytoplasm of normal germinal center B cells and lymphomas of GCB derivation . Gualco et al reported that the inclusion of HGAL in the Hans immunohistological algorithm improved the detection of the GCB subtype of DLBCL . In our study, the HGAL staining results matched those predicted by the Hans model in 82% (9/11) of cases.…”

Section: Discussionsupporting

confidence: 71%

Characteristics of diffuse large B‐cell lymphoma in patients with primary Sjögren's syndrome

2020

View full text Add to dashboard Cite

Aim: Patients with primary Sjögren's syndrome (pSS) have an increased risk of developing diffuse large B-cell lymphoma (DLBCL), which is an aggressive and heterogeneous non-Hodgkin lymphoma. This study aimed to characterize DLBCLs in patients with pSS. Method: We identified 18 patients with DLBCL and pSS over a 22-year period. Based on the 2016 WHO guidelines, we characterized DLBCL based on immunohistochemical tests using a broad panel of antibodies, and an Epstein-Barr virus (EBV) test using in situ hybridization. Results: The median time from initial pSS symptom onset to the DLBCL diagnosis was 20.5 years and the median time from the pSS diagnosis until the DLBCL diagnosis was 14 years. After the lymphoma diagnosis, the median overall survival was 3 months (range: 0-212 months) and the 5-year overall survival rate was 37.5%. Thirteen DLBCLs were re-classified as DLBCL, not otherwise specified (NOS) in nine cases; EBV-positive DLBCL, NOS in two cases; and T-cell/histiocyte-rich large B-cell lymphoma in two cases. Five cases of DLBCLs were not re-classified because theirEBV status was unknown. The Hans algorithm, which uses a combination of staining for CD10, BCL6, and MUM1, was used to classify the DLBCLs into the germinal center B-cell (GCB) subtype for three cases and the non-GCB subtype for nine cases. Conclusion:These results indicate that DLBCL tends to occur late in pSS cases and is mainly related to the non-GCB subtype of DLBCL.

show abstract

Section: Discussionsupporting

confidence: 71%

Characteristics of diffuse large B‐cell lymphoma in patients with primary Sjögren's syndrome

2020

View full text Add to dashboard Cite

show abstract

“…GCET1 positivity in DLBCL ranges from 15% to 47% in the literature [ 18 , 32 , 33 , 34 , 35 , 36 ]. In the present study, GCET1 was found to be positive in 35.4% of cases, in accordance with the literature.…”

Section: Discussionmentioning

confidence: 99%

Value of GCET1, HGAL (GCET2), and LMO2 in the Determination of Germinal Center Phenotype in Diffuse Large B-cell Lymphoma

Berker¹,

Yeğen²,

Dogan³

2023

Tjh

View full text Add to dashboard Cite

Objective: Diffuse large B-cell lymphoma (DLBCL) is a biologically heterogeneous disease that is classified into germinal center B-cell (GCB) and non-GCB subtypes, which are prognostically different. The Hans algorithm is the most widely used tool based on CD10, BCL6, and MUM1 expression, but some cases with the non-GCB phenotype are still known to be misclassified. In this study, we investigate the extent to which GCET1, HGAL, and LMO2 protein expressions reflect GCB phenotype together with their roles in determining the GCB phenotype of DLBCL and their contributions to the performance of the Hans algorithm. Materials and Methods: Sixty-five cases of DLBCL-not otherwise specified, 40 cases of follicular lymphoma (FL), and 19 non-GC-derived lymphoma cases were included in this study. The DLBCL cases were grouped as CD10 + (Group A) or only MUM1 + (Group B), and the remaining cases constituted the intermediate group (Group C). GCET1, HGAL, and LMO2 expressions were evaluated. Results: In the FL group, GCET1, HGAL, and LMO2 were positive in 85%, 77.5%, and 100% of the cases, respectively. Among the non-GC-derived lymphoma cases, all three markers were negative in cases of small lymphocytic lymphoma, plasmablastic lymphoma, peripheral T-cell lymphoma, and anaplastic large cell lymphoma. GCET1 and HGAL were negative in cases of marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL). Two of the 3 MZL and 2 of the 4 MCL cases were positive for LMO2. In the DLBCL group, the number of cases with GCET1, HGAL, and LMO2 positivity was 18 (90%), 17 (85%), and 20 (100%), respectively, in Group A and 0 (0%), 2 (13.3%), and 2 (13.3%), respectively, in Group B. Considering these rates, when the cases in the intermediate group were evaluated, it was concluded that 13 cases typed as non-GCB according to the Hans algorithm may have the GCB phenotype. Conclusion: GCET1, HGAL, and LMO2 are highly sensitive markers for determining the germinal center cell phenotype and can increase the accuracy of the subclassification of DLBCL cases, especially for cases that are negative for CD10.

show abstract

“…Meyer et al [15] included GCET1 and LMO2 as GC markers and FOXP1 as ABC marker. HGAL/GCET2 is also considered to be a GC marker [16]. CD30 positivity may be observed in 10-20% patients with DLBCL [17].…”

Section: Discussionmentioning

confidence: 99%

Gastrointestinal Manifestations of Mature B Cell Neoplasms: Single Center Experiences from the Collective Perspective of Hematology and Pathology

Demirci

Kurt

Gülsaran

et al. 2021

Preprint

View full text Add to dashboard Cite

Introduction: Hematological malignancies are frequently affecting the gastrointestinal (GI) tract, either by secondary extra nodal or extramedullary extension to the GI tract, or as a primary process arising in the GI tract. Gastrointestinal non-Hodgkin lymphomas (gNHL) appear less than other solid organ tumours in the GI tract. Therefore, in the absence of nodal or extra nodal involvement in imaging methods, there may be difficulties in diagnosis. Haematologists provide more important support by pathologists in terms of diagnosis than imaging methods.Methods: We retrospectively investigated all B-cell lymphoma patients diagnosed in our clinic between 01.01.2015- 01.01.2021. After that, patients not diagnosed by gastrointestinal system sampling were excluded from the study. Demographic data of these patients were obtained from the hospital information system and outpatient clinic files. Slides of these patients were obtained from pathology archive and re-evaluated under light microscope by two pathologists. All cases were diagnosed according to revised World Health Organization (WHO) 2017 classification.Results: 55 patients were diagnosed with B-cell lymphoma by sampling by endoscopy or colonoscopy. 40 of the patients were diagnosed with Diffuse Large B Cell Lymphoma (DLBCL), 10 with Marginal Zone Lymphoma (MZL), 2 with Mantle Cell Lymphoma (MCL), 2 patients with Burkitt Lymphoma (BL) and 1 patient with Lymphoplasmacytic Lymphoma (LPL).Conclusion: Like the literature, the frequency of DLBCL was the highest in patients diagnosed with GI tract in our study. The second most common B-cell lymphoma was MALToma. Although MCL is with a high frequency of GI involvement, there were few patients diagnosed with GI involvement. The reason for this was that the patients were diagnosed with nodal involvement rather than GI sampling.

show abstract

The contribution of HGAL/GCET2 in immunohistological algorithms: a comparative study in 424 cases of nodal diffuse large B-cell lymphoma

Cited by 8 publications

References 26 publications

Characteristics of diffuse large B‐cell lymphoma in patients with primary Sjögren's syndrome

Characteristics of diffuse large B‐cell lymphoma in patients with primary Sjögren's syndrome

Value of GCET1, HGAL (GCET2), and LMO2 in the Determination of Germinal Center Phenotype in Diffuse Large B-cell Lymphoma

Gastrointestinal Manifestations of Mature B Cell Neoplasms: Single Center Experiences from the Collective Perspective of Hematology and Pathology

Contact Info

Product

Resources

About